• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Will unpredictable side effects dim the promise of new Alzheimer ’s drugs?
A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months. As many neurologists, patients, and brain scientists celebrate, they’re also nervously eyeing complications from treatment: brain swelling and bleeding, which in clinical trials affected up to about one-third of patients and ranged from asymptomatic to fatal. The side effect—amyloid-related imaging abnormalities, or ARIA—remains mysterious. “We don’...
Source: Science of Aging Knowledge Environment - August 2, 2023 Category: Geriatrics Source Type: research

Clinical trial participant ’s autopsy and brain exam stoke Alzheimer’s drug fears
A full autopsy and detailed examination of the brain of a 79-year-old Florida woman who died after receiving lecanemab, an experimental Alzheimer’s therapy, in a pivotal clinical trial has deepened some researchers’ concerns that it poses serious risks for patients who share the woman’s hard-to-diagnose, preexisting condition. The patient’s history and autopsy “strongly suggests that lecanemab infusions were a catalyst leading to the events resulting in her death,” says Vanderbilt University pathologist Hannah Harmsen, co-author of a recently completed case report, which Science has obtained. The aut...
Source: Science of Aging Knowledge Environment - April 13, 2023 Category: Geriatrics Source Type: research

Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota. Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research

MRI for all: Cheap portable scanners aim to revolutionize medical imaging
.news-article__hero--featured .parallax__element{ object-position: 47% 50%; -o-object-position: 47% 50%; } The patient, a man in his 70s with a shock of silver hair, lies in the neuro intensive care unit (neuro ICU) at Yale New Haven Hospital. Looking at him, you’d never know that a few days earlier a tumor was removed from his pituitary gland. The operation didn’t leave a mark because, as is standard, surgeons reached the tumor through his nose. He chats cheerfully with a pair of research associates who have come to check his progress with a new and potentially revolutionary device they are testing. The cylind...
Source: Science of Aging Knowledge Environment - February 23, 2023 Category: Geriatrics Source Type: research

As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research

Stroke Risk Among Elderly Users of Haloperidol and Typical Antipsychotics Versus Atypical Antipsychotics: A Real-World Study From a US Health Insurance Claims Database
Antipsychotics are approved and prescribed to treat various conditions such as schizophrenia, mania, major depressive disorder, agitation, delusional disorder, psychosis, and Tourette's syndrome.1 The haloperidol prescribing information2 in the United States (US) does not warn about the risk of stroke but has a black box warning for an increased risk of death among elderly patients with dementia-related psychosis treated with antipsychotic drugs. Nonetheless, antipsychotics are used for indications such as neuropsychiatric symptoms of dementia, in the presence or absence of psychosis; such use is not approved by the Food a...
Source: The American Journal of Geriatric Psychiatry - September 26, 2020 Category: Geriatrics Authors: Daniel Fife, Clair Blacketer, R. Karl Knight, James Weaver Tags: Regular Research Article Source Type: research

Stroke Risk among Elderly Users of Haloperidol and Typical Antipsychotics vs. Atypical Antipsychotics: A Real-World Study from a US Health Insurance Claims Database
Antipsychotics are approved and prescribed to treat various conditions such as schizophrenia, mania, major depressive disorder, agitation, delusional disorder, psychosis, and Tourette's syndrome1. The haloperidol prescribing information2 in the United States (US) does not warn about the risk of stroke but has a black box warning for an increased risk of death among elderly patients with dementia-related psychosis treated with antipsychotic drugs. Nonetheless, antipsychotics are used for indications such as neuropsychiatric symptoms of dementia, in the presence or absence of psychosis; such use is not approved by the Food a...
Source: The American Journal of Geriatric Psychiatry - September 25, 2020 Category: Geriatrics Authors: Daniel Fife, Clair Blacketer, R. Karl Knight, James Weaver Source Type: research